Peter Fernandes - Jun 7, 2023 Form 4 Insider Report for Bellerophon Therapeutics, Inc. (BLPH)

Role: Chief Executive Officer, Principal Financial and Accounting Officer
Signature: /s/ Peter Fernandes
Stock symbol: BLPH
Transactions as of: Jun 7, 2023
Transactions value $: $0
Form type: 4
Date filed: 6/9/2023, 04:12 PM
Previous filing: Feb 14, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BLPH	Stock Options (Right to Buy)	Award	$0	-100K	-50%	$0.00	100K	Jun 7, 2023	Common Stock	100K	$0.83	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option was approved by the Compensation Committee of the Board of Directors of Bellerophon Therapeutics, Inc., on February 10, 2023, contingent upon stockholder approval of an amendment to the Company's 2015 Equity Incentive Plan under which the options were granted, which was approved by stockholders on June 7, 2023.
F2	This option vests in 16 quarterly installments commencing on the date hereof.

Remarks:

Chief Executive Officer, Principal Financial and Accounting Officer